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Protective immunization with plasmid DNA 
containing the outer surface lipoprotein A gene of 
Borrelia burgdorjeri is independent of an 
eukaryotic promoter 
Plasmid DNA encoding the outer surface lipoprotein A (OspA) of Borreliu 
burgdorferi under the control of either strong eukaryotichiral or its own bacte- 
rial promoter was injected intramuscularly (m. tibialis anterior) or intradermally 
into BALB/c and AKIUN mice. OspA-specific antibodies and OspA-reactive T 
helper 1 cells (Thl) were induced only with those plasmids containing the ospA 
structural gene including its own regulatory control region immediately 
upstream. In the absence of the ospA promoter, no or only marginal immune 
responses to OspA were obtained, even when strong eukaryotic promoter/ 
enhancer elements were present. Together with the finding that the ospA promo- 
ter is active in a mouse B-lymphoma line, the data suggest that spirochetes are 
able to express at least part of their genes in the mammalian environment. Mice 
previously vaccinated with the relevant ospA plasmid DNA were protected 
against subsequent experimental challenge with a virulent strain of B. burgdor- 
feri, as measured by the appearance of antibodies to a prominent protective epi- 
tope (LA-2) and the failure to re-isolate spirochetes from ear biopsies. In addi- 
tion, C.B-17 severe-combined immunodeficient mice could be protected against 
infection by passive transfer of immune sera from ospA plasmid DNA- 
inoculated normal mice. Protective LA-2-related antibody titers obtained after 
repeated immunization persisted for 200 days and longer. This simple procedure 
of immunization using plasmid DNA consisting of a prokaryotic gene under the 
control of its own promoter holds great promise for the development of alternat- 
ive subunit vaccines against bacterial infections, including Lyme disease. In 
addition, the availability of this novel prokaryotic promoter element now allows 
the study of the basis for the differential expression of bacterial genes in proka- 
ryotic and eukaryotic environments. 
1 Introduction 
Lyme borreliosis is the leading vector-borne bacterial dis- 
ease in Europe and USA [l]. The etiological agent, Borre- 
liu burgdorferi, is primarily transmitted by the globally dis- 
tributed ticks of the genus Zxodes. Dissemination of spiro- 
chetes through the blood and lymph occurs early after 
infection and may lead to a multisystem illness with mani- 
festations in the skin, heart, musculoskeletal, and central 
nervous system [ 11. Although patients can be successfully 
treated with antibiotics in the early stage of disease, it is 
unclear whether currently applied regimens always lead 
to the eradication of spirochetes [2]. Furthermore, 
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spirochete-specific humoral and cellular immune respon- 
ses generated during infection do not always protect pati- 
ents against the development of disease [l]. 
In search for a suitable polypeptide vaccine against Lyme 
disease, the outer surface lipoprotein A (OspA) has been 
found to be the most promising candidate in mice [3-51. It 
was found that immunization of mice with recombinant 
OspA lipoprotein (rlipOspA) leads to the activation of B 
and Tcells and that both lymphocyte populations are 
essential for the generation of optimal levels of protective 
antibodies [6]. However, because of the antigenic variation 
of OspA within the species of B. burgdorferi sensu lato [7, 
81, the cross-protective potential of antibodies generated 
to one particular OspA genotype is still debated [9-111. At 
present, rlipOspA, which has been shown to be safe, clin- 
ically well-tolerated, and immunogenic [12, 131, is being 
tested for its efficacy in phase I11 clinical trials. In spite of 
these achievements, the major drawback of this approach 
is the time-consuming and costly procedure inherent to the 
production of recombinant polypeptide vaccines. 
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were shown to be maintained in an episomal, circular form 
and do not replicate [14, 15, 181. The expression of prote- 
ins, however, persisted in tissues of skeletal muscle and 
heart for several months [18, 191. This novel technique, 
termed DNA-based vaccination, has been applied to viral 
[16, 20, 211, mycoplasma [22], and parasite antigens [23], 
and was shown to result in protection against infection. 
We now show that DNA-based vaccination is also suitable 
to introduce outer surface proteins of B. burgdorferi, such 
as OspA, into the antigen processing pathway and to gen- 
erate both protective humoral and cellular responses in 
mice. Most importantly, ospA gene expression was found 
to be independent of eukaryotic promoter/enhancer elem- 
ents. The fact that bacterial genes can be independently 
activated in the eukaryotic environment may have import 
implications for pathogenesis and protection in the 
infected host. 
2 Materials and methods 
2.1 Animals and immunization protocol 
Adult female BALB/c, AKR/N, and C.B-17.SCID mice (6 
to 8 weeks old) were bred under specific pathogen-free 
conditions at the Max-Planck-Institut f i r  Immunbiologie, 
Freiburg, Germany. BALB/c and AKR/N mice were 
repeatedly immunized by injection into tibialis anterior 
muscles (i.m.) or i.d. into the hind legs, with various doses 
of plasmid DNA containing ospA or control plasmids. 
2.2 Bacteria and recombinant OspA lipoprotein 
The virulent low-passage tick isolate B. burgdorferi ZS7 
was grown in Barbour-Stoenner-Kelly medium and har- 
vested as described [3]. rlipOspA and the delipidated 
derivative of IipOspA, Met.-Asp-Pro-OspA (MDP-OspA) 
were expressed in Escherichia coli according to previously 
described protocols. The recombinant protein prepara- 
tions were purified by gel filtration (HR-4009), butanol 
extraction and Q-Sepharose chromatography [ l l ,  241. 
2.3 Construction and purification of expression vectors 
Large-scale purification of expression vectors was con- 
ducted using the Qiagen Plasmid Mega Kit System (Qia- 
gen GmbH, Hilden, Germany), according to the protocol 
of the manufacturer. Purified plasmids used in this study 
(Fig. l a ,  b) were adjusted to a final DNA concentration of 
1 mg/ml. 
Plasmid pBosOspA contains the ospA gene from B. burg- 
dorferi ZS7, including 140 bp of its immediately upstream 
control region (Fig. lb) [25] cloned into the Bst XI site of 
pEF-Bos that contains the promoter/enhancer region of 
the human elongation factor la (EF-la) gene (Fig. la)  
[26]. Plasmid pBosOspAr harbors the identical ospA gene 
fragment in the inverted orientation. The same ospA gene 
fragment was also cloned into the Bam HI site of plasmid 
pKEX-1 containing the promoter/enhancer region of the 
human cytomegalovirus (HCMV-IE) [27] and pBSIISK' 
(Stratagene, Heidelberg, Germany) to generate pKEX- 
OspA and pOspA, respectively. Plasmid pOspAcod was 
generated from pOspA by deleting the 140-bp DNA frag- 
ment containing the ospA upstream control region. pBos- 
OspA17/48 was generated in a similar way with the excep- 
tion that a 200-bp DNA fragment (bp - 140 to bp + 60) 
containing the ospA upstream control region and the 
nucleotide sequence encoding the 20 N-terminal amino 
acids of OspA was deleted [25,28]. Plasmids were propag- 
ated in the E. coli strain DHSa (GIBCO BRL, Eggens- 
tein, Germany). The nucleotide sequence of ospA has 
been submitted to the EMBL database with the accession 
number X16467. 
2.4 'Ikansfection and Northern blot analysis 
The mouse B-lymphoma K46 [29] was propagated and 
transfected by electroporation as described [30] except 
that 20 pg of each plasmid was used. After 36 h, cells were 
washed twice in ice-old PBS and resuspended (1 x 107-2 x 
10') in ice-cold TNE (10 mM Tris-HCI pH 7.5, 1 mM 
EDTA, 10 mM NaCI). Total cytoplasmic RNA was 
extracted by lysing the cells in 0.1% NP40, followed by 
centrifugation at 7600 x g for 5 min at 4"C, followed by 
phenol extraction of the supernatant containing the RNA. 
Northern blot analysis of equal amounts of RNA from 
each transfection was performed by standard procedures 
[31] using a radiolabeled OspA probe (gel-isolated from 
Bam HI-digested pOspA). As a loading control, a mouse 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
cDNA probe was used. 
2.5 ELISA, mAb LA-2 competition ELISA and Western 
blot analysis 
B. burgdorferi-specific antibodies (IgM, IgG, IgG1, 
IgG2a, IgG2b, and IgG3) were measured in a solid-phase 
ELISA as described [32], with the modification that plates 
were pre-coated with rlipOspA (1 pg/ml) instead of spiro- 
chete lysate. 
Antibodies with the same specificity as the mAb LA-2, 
which was shown before to be protective in a mouse model 
for B. burgdorferi infection [3], were measured by a com- 
petition ELISA. Briefly, wells of ELISA microplates 
(Nunc Immunoplate Maxisorp, Rostilde, Denmark) were 
coated overnight at 4 "C with 100 p1 rlipOspA (0.5 pg/ml in 
0.05 M, Na2COJNaHC03, pH 9.6). After washing with 
PBS containing 0.05 % Tween 20 (PBS-T), the plates were 
incubated with 200 pl PBS/1 YO BSA for 30 min at room 
temperature with shaking. Subsequently, wells were incub- 
ated for 2 h with 100 pl of serial twofold dilutions of 
mouse sera diluted in PBY0.2 % BSA containing 0.05 % 
Tween 20. For the calibration curve, mouse serum was 
replaced by serial twofold dilutions of purified mAb LA-2 
(highest concentration: 4 pg/ml). After washing, a limiting 
concentration of mAb LA-2, conjugated to peroxidase (in 
PBSBSA 0.2 YO, 0.05 % Tween 20; amount of peroxidase- 
labeled mAb LA-2 was adjusted to a concentration suffi- 
cient to reach the plateau level in a previous competition 
assay with rlipOspA) was added to each well. The deter- 
mination of this critical concentration of peroxidase- 
labeled mAb LA-2 is important to achieve maximal sensi- 
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tivity of the assay. Plates were incubated for 30 min at 
room temperature with shaking. After washing, 100 pi 
substrate solution [4 mg o-phenylenediamine (Sigma 
P 8787, St. Louis, MO) in 10 ml 0.1 M citrate pH 4.5 + 
5 p1 30% H202] was added to each well. After a 15-min 
incubation at room temperature in the dark, the reaction 
was stopped by addition of 50 yl 1 N HCl. The absorbance 
was read at 490 nm using an ELISA plate reader. The 
absorbance was converted in equivalents of mAb LA-2 
using the calibration curve and the 4-parameter method. 
acrylamide gels and transferred to nitrocellulose. Subse- 
quently, individual nitrocellulose stripes were incubated 
with the respective sera (diluted 1 : 100 followed by goat 
anti-mouse IgM, IgG, IgG1, IgG2a, IgG2b or IgG3 anti- 
bodies labeled with alkaline phosphatase as the second 
reagent as described [32]. 
2.6 T cell proliferation assay and test for cytokine 
production 
For immunoblotting, spirochetes (strain ZS7) were lysed 
in SDS buffer, separated by SDS-PAGE on 12 % poly- 
Lymph node (a pool of axillary, inguinal and popliteal) or 
spleen cells were enriched for Tcells by treatment for 2 h 
a 
14-mer 14-mer 
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Figure 1. (a) ospA plasmid constructs used for DNA vaccination. The B. burgdorferi ZS7 ospA encoding gene (vertically hatched bars) 
including 140 bp (horizontally hatched bars) of its upstream control region was inserted in both orientations (sense = pBosOspA; anti- 
sense = pBosOspAr) into the Bst XI site of pEF-Bos that contains the promoter/enhancer region of the human EF-la chromosomal 
gene [26]. Plasmid pKEXOspA contains the identical ospA gene fragment under the control of the HCMV-IE promoter/enhancer ele- 
ment cloned into the Bst XI site of pKEX-1 [27]. Similarly, the same ospA gene fragment was cloned into the Bam HI cloning site of 
pBSIISK' to generate pOspA. Plasmid pOspAcod is identical to pOspA except that the upstream control region of ospA was deleted. 
Plasmid pBosOspA17/48 is identical to pBosOspA, with the exception that a 200-bp deletion at the 5' end of the ospA gene fragment 
(bp - 140 to bp + 60) was introduced and instead, an artifical ATG start codon was inserted. (b) Nucleotide sequence of the upstream 
control region of the ospA gene in B. burgdorferi ZS7. The respective - 35 (TTGTTA) and - 10 (TATAAT) regions of the promoter, 
ribosome binding sites (RBS) and the transcriptional start point (+ 1) are underlined. Direct repeats of the 14-base sequence (14-mer) 
are indicated by double underlines. 
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with magnetic beads coated with goat anti-mouse IgG 
F(ab'), (Paesel, Frankfurt, Germany). The resulting cell 
preparations were analyzed by FACS and consisted of 
> 94 YO (spleen) or > 98 YO (lymph node) Tcells (CD3+), 
and < 3 YO (spleen) or < 1 % (lymph node) B cells (Ig'). 
Enriched Tcells (2 x lo5) from mice previously immun- 
ized twice with either pEF-Bos (control plasmid), pBos- 
OspA or pOspA were incubated with preparations of 
either sonicated B. burgdorferi organisms (20 pg protein/ 
ml), IipOspA or MDP-OspA (2 pg/ml) in culture medium 
(Iscove's, 20% FCS) in a total volume of 200 pl in round- 
bottom Microwell plates (Nunc). Production of cytokines 
was measured in culture supernatants obtained after 24 h. 
Proliferation was assessed in triplicate on day 3 by adding 
[3H]thymidine for the last 12 h. 
Supernatants were tested for IFN-y and IL-4 using mAb 
pairs R4-6A2/XMG1.2 and 11B 11/BVD4- 1D11, respec- 
tively (PharMingen, San Diego; CA) in standard sandwich 
ELISA according to the manufacturer's instructions. 
2.7 Challenge experiments and protection 
2.7.1 Passive protection 
SCID [H-2d] mice were reconstituted with either pooled 
immune sera (IS) of OspA plasmid DNA (p0spA)- 
immunized BALB/c mice or mAb LA-2 [33] or PBS. The 
IS transferred were adjusted to contain 5 pg LA-2 equival- 
ents (totaYmouse). IS or mAb LA-2 (5 pg/mouse) were 
given i.p. and 1 h later, the recipients were challenged 
experimentally (s.c.) with lo5 B. burgdorferi ZS7. Mice 
were monitored for the development of clinical arthritis 
under blinded conditions and for the presence of spiroche- 
tes by cultivating ear biopsies in BSK medium after 27 
days as described [9,34]. The development of clinical arth- 
ritis in the tibiotarsal joints was scored as described [35] 
using swelling and reddening as criteria: + + , severe; +, 
prominent; (+), moderate; +/-, mild; (+/-), mainly 
reddening without significant swelling; and -, no clinical 
signs of arthritis. At the end of the observation period (day 
27), mice were killed and the joints and heart were fixed in 
10 YO formaldehyde and embedded in paraffin wax. Tissue 
sections were scored in a blinded fashion for histological 
alterations as described [35]. 
2.7.2 Active protection 
BALBk mice previously immunized with either pBos- 
OspA, pOspA, pEF-Bos or left untreated, were experi- 
mentally challenged either once or repeatedly with 1 x lo4 
or 1 X lo6 spirochetes (ZS7). Between 12 and 96 days 
post-infection (p.i.) mice were investigated for the pres- 
ence of spirochetes by the cultivation of ear biopsies as 
described [32]. 
3 Results 
3.1 Immunization of mice with plasmid DNA containing 
the OspA gene leads to the production of specific 
antibodies 
BALB/c and AKR/N mice were repeatedly inoculated with 
the indicated plasmid DNA (Fig. la)  in the quadriceps of 
both legs. OspA protein expression was demonstrated by 
analyzing the production of OspA-specific antibodies on 
rlipOspA by ELISA (Table 1) or by Western blot (Fig. 2). 
After the first immunization with pBosOspA, monospecific 
antibodies to OspA were already detectable in both mouse 
strains when tested on day 30 p.i. (Table 1, experiment 1; 
Fig. 2). In contrast, OspA-specific antibodies could not be 
detected in mice immunized with pEF-Bos (control plas- 
mid). The amount of antibodies significantly increased with 
further immunizations, reaching plateau levels of more 
than 0.5 mg/ml in BALB/c and AKR/N mice after the sec- 
ond or third boost. The antibody response was dose- 
dependent, with higher amounts of DNA providing a faster 
immune response as well as higher antibody titers (Table 1, 
exp. 2). Similar antibody titers were also obtained from 
BALB/c mice following intradermal delivery of pBosOspA 
(Table 1, exp. 3). For comparison, pooled sera from mice 
infected with 10' spirochetes contained - 0.3 mg/ml OspA- 
specific antibodies; hyperimmune sera from rlipOspA- 
immunized mice contained - 4 mg/ml OspA-specific 
antibodies (Table 1). When eukaryotic and viral promo- 
tors, i.e. EF-la (pEF-Bos) and HCMV-IE (pKEX-I), were 
compared for their efficacy to induce OspA-specific antibo- 
dies in BALB/c and A K W  mice, the EF-la promoter was 
more efficient (Table 1, exp. 4). This is in line with previ- 
ous results and indicates that EF-la has a higher potential 
than HCMV-IE to direct transcription and translation of 
ospA [26]. Surprisingly, immunization of mice with pBos- 
OspAr harboring the ospA gene in the inverse orientation 
also led to the generation of OspA-specific antibodies with 
kinetics and titers similar to those observed with pBos- 
OspA (Table 1, exp. 1). This indicated that the eukaryotic 
EF-la promoter is not essential for high expression of 
OspA in mice. This assumption was verified by showing 
that the application of pOspA, which contains the ospA 
gene of B. burgdorferi ZS7 including its upstream control 
region but lacks any eukaryotic promoter sequences, also 
led to the production of OspA-specific antibodies in 
BALB/c mice (Table 1, exp. 5; representative of three 
independent experiments). Following the fourth immun- 
ization with pOspA, IS of these mice contained OspA- 
specific antibodies at levels (0.5 mg/ml) similar to those 
observed with pBosOspA. No or only marginal levels of 
OspA-specific antibodies were observed in mice immun- 
ized with either pOspAcod (Table 1, exp. 5) or pBosOs- 
pA17/48 (Table 1, exp. 1). 
3.2 Transient transfection of target cells with plasmid 
DNA containing the OspA gene results in expression 
of specific mRNA 
That the ospA promoter is also active in eukaryotic cells 
was directly tested by transiently transfecting several 
OspA expression plasmids into the mouse B-lymphoma 
K46, followed by Northern blot analysis of cytoplasmic 
RNA. Fig. 3 shows that the ospA promoter alone (lane 4) 
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Table 1. Development of OspA-specific antibodies in serum of BALBIc and AKR/N mice repeatedly immunized with plasmid DNA 
containing ospA"' 
Genetic immunization against Lyme disease 
Exp . Mouse Plasmid or Amount of anti-OspA (LA-2 equivalents*) antibodies (pglml) Control 
strain immunogen lS' 2"d (LA-2)* 3'd (LA-2)* 4'h (LA-2)* IS 
1 
2 
3 
4 
5 
Con- 
trol 
BALBlc 
AKR/N 
BALBlc 
BALBIc 
BALBIc 
AKRM 
BALBIc 
BALBIc 
BALBIc 
PEF-Bos 
pBosOspA 
pBosOspAr 
pBosOspA17148 
pBosOspA 
pBosOsp Ar 
pBosOspA17148 
pBosOspA 
PEF-Bos 
50 Yg 
0.5 Pg 
5 
pBosOspA 
pBosOspA 
pKEXOspA 
pBosOspA 
pKEXOspA 
pOspAcod 
10' B. burgdorferi 
z s 7  
rlipOspA 
POSPA 
<0.1 <0.1 
13 474 
24 197 
t 0 . 1  <0.1 
t 0 . 1  <0.1 
nd 1100 
20 616 
<0.1 <0.1 
15 
3.2 
(< 0.5) 
(137) 
(75) 
(455) 
( 4  
(1.6) 
(7.4) 
(< 0.5)  
(< 0.5) 
( (0 .5)  
1.4 (0.7) 
282 (21.2) 
75 (40) 
10 (7.6) 
129 (103) 
19 (7.6) 
20 (1.8) 
<0.1 
641 
306 
534 
583 
224 
45 
15 
926 
150 
105 
236 
30 
203 
< 0.1 
308 (28) 
4074 (1120) 
a) BALBIc and AKRM mice were immunized one to four times with the indicated plasmids (50 pg: exp. 1 ,3 ,4 ,5 ;  50 pg, 5 pg, 0.5 pg: 
exp. 2). Sera were taken at the following intervals p i :  Exp. 1: first, day 35 p i . ;  second, day 15; third, day 15; Exp. 2: second, day 
7; third, day 9; fourth, day 98; Exp. 3: second, day 8; third, day 9. Exp. 4: second, day 7; third, day 6; and Exp. 5: second, day 6; 
third, day 7; fourth, day 7. Pooled sera (five mice) were tested for OspA-specific antibodies by ELISA on rlilpOspA and for LA-2- 
related specificity in competitive ELISA as described in Sect. 2.5. BALBlc anti-10' B. burgdorferi. ZS7 IS is a hyperimmune serum 
pool derived from various bleedings taken between days 30 and 80 p i . ;  BALBIc anti-rlipOspA IS is a hyperimmune serum pool 
derived from various bleedings taken between days 10-80 following the third immunization with rlipOspA (10 pg in ABM adjuvant, 
three times, biweekly intervals). 
is several times stronger than the strong eukaryotic EF-la 
promoter (lane 3) and that both promoters act synergistic- 
ally when arranged in tandem on the same plasmid 
(lane 2). Transfection with a construct carrying neither the 
EF-12 promoter nor the ospA promoter (lane 5) shows, if 
at all, very weak expression. Notable features of the 
sequence upstream of the OspA protein-encoding region 
include two closely spaced repeats of the 14-base sequence 
AACCAAACITAATT, as well as two direct repeats of the 
- 35 (TTGTTA) and - 10 (TATAAT) boxes (Fig. lb). 
70 - 
60 - 
41 - 
34 - 
31 - 
ti  = 
7.5 - 
I I I  
Figure 2. Isotypes (IgM, IgG1, IgG2a, IgG2b, 
and IgG3; four lanes each) of OspA-specific 
antibodies generated in BALBlc and AKR/N 
mice previously immunized (i.m.) once (I ,  day 
0) or twice (11, day 35) with either pBosOspA 
(50 pg, lanes 1 and 3) or pBosOspAr (50 pg, 
lanes 2 and 4). Sera were taken at day 30 after 
the first and at day 10 following the second chal- 
lenge (pool of five mice) and dilutions tested by 
Western blot analysis on ZS7 lysate. Lanes 1 
and 2: BALBlc; lanes 3 and 4: AKR/N. 
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OspA 
Gapdh 
1 2 3 4 5  
Figure 3. Northern blot analysis of OspA mRNA expression. The 
mouse B-lymphoma K46 was transiently transfected with the indi- 
cated plasmids and total cytoplasmic RNA was analyzed using a 
radiolabeled OspA probe (see Sect. 2.4). To control for equal 
loading of RNA, the blot was rehybridized with a probe for the 
ubiquitous mRNA encoding GAPDH. 
3.3 Analysis of isotype patterns of anti-OspA antibodies 
and of OspA-specific T cells generated in response to 
plasmid DNA immunization 
As shown in Fig. 2, IS from BALBk and AKR/N mice 
immunized once (i.m.; Fig. 2 I) with pBosOspA contained 
antibodies of the isotypes IgG1, IgG2a and IgG2b and lit- 
tle, if any IgG3, when tested 30 days post infection; no 
OspA-specific IgM antibodies were detectable at this time 
point. After the second boost (i.m.; Fig. 2II), IS of both 
mouse strains also contained OspA-specific antibodies of 
the IgG3 isotype. Similar isotype patterns were observed 
following immunization using the plasmid pOspA (data 
not shown). 
The appearance of IgGl and IgG3 antibodies to OspA in 
sera of mice following the first and second challenge, 
respectively, indicates that plasmid DNA immunization 
also leads to the induction of OspA-reactive T cells. To test 
this assumption, spleen and lymph nodes were removed 
from BALB/c and AKlUN mice after the boost with either 
pEF-Bos or  pBosOspA. Enriched T cell populations 
(>90% pure) were restimulated in vitro with either 
B.  burgdorferi ZS7 sonicate, rlipOspA or MDP-OspA or 
cultured in medium alone (Table 2). The proliferation 
rates of spleen and lymph node Tcells previously sensit- 
ized in vivo to pBosOspA was approximately three and 
eight times higher, respectively, compared to control 
Tcells when restimulated with MDP-OspA (Table 2, only 
shown for AKIUN mice). The differences in proliferative 
responses between naive and sensitized T cell populations 
were much less pronounced in the presence of B. burgdor- 
feri sonicate or rlipOspA, an observation which is not 
unexpected in light of the recent findings that spirochete 
lipoproteins exhibit co-stimulatory activities for naive 
Tcells [36, 371. In addition, splenic Tcells from 
pBosOspA- but not from pEF-Bos-inoculated AKR/N 
mice produced significant amounts of I F N y  , but no IL-4 
(data not shown) upon restimulation in vitro with MDP- 
OspA (Table 2). Similar results were obtained with Tcells 
from pBosOspA-immunized BALB/c mice as well as with 
Tcells from BALB/c and AKR/N mice previously sensit- 
ized to pOspA (data not shown). 
3.4 Immunization of mice with plasmid DNA containing 
the OspA confers active and passive protection 
against challenge with B. burgdorfen' 
It has been shown that antibodies with specificity to the 
OspA epitope LA-2 [33] induced in hamsters [38], mice 
and dogs [39] could protect against challenge by infected 
ticks and/or by needle injection that as little as 0.3 pg mAb 
LA-2 was sufficient to protect hamsters. In addition, it was 
found that sera from monkeys and human volunteers 
immunized with rlipOspA can confer protection against 
experimental infection; in that case, 1 pg/ml LA-2-specific 
antibody was sufficient to achieve protection (Hauser and 
Voet, unpublished observation). We therefore tested IS 
from mice previously immunized with the plasmids shown 
in Fig. l a  for the presence of LA-2-related antibody spe- 
cificities. As seen in Table 1, with no exception, all DNA 
vaccination protocols that resulted in the generation of 
OspA-specific antibodies also led to the induction of those 
related to the LA-2 epitope. After the third immunization, 
Table 2. Induction in vivo of OspA specific Tcells in mice immunized with plasmid DNA containing OspAa) 
Spleen T cells LN T cells 
pBosOspA pEFBos pBosOspA pEFBos 
Proliferation IFN-y Proliferation IFN-y Proliferation Proliferation 
Addition to cultu- cpm f SD Ulml cpm f SD U/ml cpm f SD cpm f SD 
re 
- 3632 f 222 6.5 1211 f 178 < 5  520 f 63 171 k 11 
B. burgdorferi 26 128 & 2899 11 12077 f 2511 <5 1303 f 210 607 f 262 
sonicate 
Lip-OspA 26355 f 2505 16 7787 f 617 < 5  1609 f 99 459 f 144 
MDP-OspA 9777 f 91 30 1671 k 24 < 5  1099 f 99 153 f 23 
a) AKR/N mice were immunized twice at day 0 and day 14 with either pBosOspA or pEF-Bos (50 pg). Seven days following the second 
challenge, spleen and lymph node (a pool of axillary, inguinal, politeal) cell populations from two mice were enriched for Tcells: 
spleen (pBosOspA: 91.8% CD3', 4.8% Ig'; pEF-Bos: 94.5% CD3', 2.4% Ig'); lymph node (pBosOspA: 96.6% CD3', 0.3% 
Ig'; pEF-Bos: 98.2% CD3', 0.7 % Ig+). Tcell populations were incubated with either B. burgdorferi ZS7 sonicate (20 pghl), Lip 
OspA (2 pghl)  or MDP-OspA (2 pg/ml) in v ibo  and tested for proliferation and the production of IFN-y and IL-4 (data not shown) 
as described in Sect. 2.6. 
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Table 3. Development of clinical arthritis and infection in C.B-17 SCID mice pre-treated with either immune serum to pOspA or mAb 
LA-2 and subsequently challenged with B. burgdorferi ZS7"' 
Clinical arthritis at day p i .  
Amount of serum or Mouse no. 7 9 16 20 27 Recultivation 
mAb transferred of spirochetes 
PBS 1 
2 
3 
1 
+ ++ ++ + + ++ + 
++ ++ + 
- - 
(+I (+) 
(*) 
(k) 
(*I 
- 
++ - - 
- - - - - - 
- - - - 
- - - - 
- Anti-pOspA 2 
(LA-2 equiv. 5 pg) 3 
mAb LA-2 (5 pg) 1 
- - - - 
- 
- - 4 
2 
3 
- - 
- - - 
(*) - 
- 
- 
- - 
- - - - - - 
~~ ~ 
a) C.B-17. SCID mice were treated with the indicated amounts of anti-pOspA immune serum (adjusted for 5 pg LA-2 equivalents) or 
mAb LA-2 or with PBS and challenged 1 h later with lo5 B. burgdorferi ZS7 spirochetes. Clinical arthritis and recultivation of spiro- 
chetes was monitored as described in Sect. 2.7. 
Table 4. Protection of mice vaccinated with ospd-plasmid DNA against experimental challenge with B. burgdorferi") 
Mouse strain Vaccinated Challenge Culture day No. positive1 
with: p.i. No. examined 
BALBlc none 1 x lo4 12 015 
1 x 104 22 114 
1 x 106 60 213 
98 u 3  
BALBlc PEF-Bos 1 x 106 55 113 
93 113 
BALBlc p ~ o s ~ s p ~  1 x 104 12 015 
1 x lo4 22 015 
1 x 106 60 015 
BALBIc POSPA 1 x 106 55 013 
93 013 
a) BALBlc mice were immunized three times with the indicated plasmid (50 pg). Fourteen days after the last challenge, mice were 
infected either once (1 x lo4 or 1 X lo6) or repeatedly with lo4 (day 30 p i )  or lo6 (day 60 p i )  ZS7 spirochetes. Infection was moni- 
tored by recultivation of spirochetes from ear biopsies at the indicated time, as described in Sect. 2.7. 
most of the IS contained more than 10% LA-2-specific 
antibodies, a level similar to that obtained after infection 
with 10' spirochetes (Table 1). Protective titers of LA-2- 
specific antibodies were observed for more than 200 
days following the third immunization with either pBo- 
sOspA or pOspA, even when only 0.5 pg plasmid DNA 
was applied (data not shown). For comparison, hyperim- 
mune sera of BALB/c mice immunized with rlipOspA con- 
sisted of 30 % LA-2-specific antibodies (Table 1). 
To test for the protective capacity of OspA-specific antibo- 
dies induced by plasmid DNA vaccination, SCID mice 
were treated with IS from pOspA-inoculated mice 
(adjusted to contain 5 pg LA-2-equivalents) or with mAb 
LA-2 (5 pg, total) and subsequently challenged with 10.5 
B. burgdorferi organisms (Table 3). Development of clin- 
ical arthritis (reddening and swelling) and recovery of spi- 
rochetes from ear biopsies were monitored. Inoculated, 
PBS-treated control SCID mice developed clinical arthritis 
starting between 9 and 16 days post challenge and resulted 
in severe swelling of the tibiotarsal joints between days 20 
and 27. Spirochetes could be recultivated from all control 
mice. In contrast, SCID mice injected either with IS from 
pOspA-inoculated mice or with mAb LA-2 did not develop 
any significant signs of clinical arthritis under similar condi- 
tions and spirochetes could not be recultivated from ear 
biopsies (Table 3). The macroscopic findings were con- 
firmed by histological examination (data not shown). 
To evaluate the protection in actively immunized animals, 
BALBlc mice were injected twice with pBosOspA, 
pOspA, or pEF-Bos (control plasmid). Mice were subse- 
quently infected either once or repeatedly with doses of 
lo4 or lo6 spirochetes ZS7 (s.c.) and monitored by re- 
isolation of spirochetes from ear biopsies. Nonvaccinated 
mice served as controls. As shown in Table 4, spirochetes 
could not be re-isolated from any of the mice vaccinated 
with pBosOspA or pOspA; in contrast, spirochetes were 
recovered, though to various extents, from untreated mice 
or mice vaccinated with the control plasmid DNA. 
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4 Discussion 
4.1 Plasmid vaccines 
In the present study, we demonstrate a new form of gene 
expression of the outer surface protein OspA of B. burg- 
dorferi, the cause of Lyme disease, in the mammalian envi- 
ronment that has not been observed before. Although 
recent publications on DNA-based immunization sug- 
gested that strong eukaryotic promoters are necessary for 
gene expression in mammals [19, 26,401, we now show by 
comparative analysis that the application of plasmid DNA 
containing the prokaryotic ospA gene including its own 
upstream regulatory region into mouse muscle or skin tis- 
sue leads to protective immunity similar to that achieved 
by immunization with the respective recombinant OspA 
lipoprotein. This approach to evoke an immune response 
against prokaryotic antigens by plasmid DNA immuniza- 
tion may be of more general applicability for the genera- 
tion of serological reagents to those bacterial genes harbor- 
ing promoter regions recognized by eukaryotic transcrip- 
tion factors. Moreover, the promoter of the bacterial ospA 
gene offers a new strategy for the development of power- 
ful mammalianhacterial shuttle vectors. 
4.2 The prokaryotic ospA gene is expressed in an 
eukaryotic environment 
It is unclear how the prokaryotic ospA gene is activated in 
the mammalian host. In light of recent observations, it is 
rather unlikely that plasmid DNA is randomly integrated 
into the host cell genome and thus subject to the control of 
eukaryotic promoter elements [18, 191. In fact, we  have 
shown by transient transfection into the mouse B- 
lymphoma line K46 that transcription from pOspA is 
stronger than from pOspA17/48. Assuming that the stabil- 
ity of the transcripts is similar, this indicates that even in 
eukaryotic cells, the upstream bacterial control region of 
ospA (140 bp) is a strong promoter able to drive the 
expression of the OspA. 
At present, it is unknown which part of the ospA promoter 
mediates transcription. The similarity in structure between 
linear plasmids of B. burgdorferi, which encode several 
surface antigens, such as OspA, B, D, E, F and pG [34] 
and some viruses, suggests a eukaryotic/viral origin of 
these linear plasmids and a possible conservation of tran- 
scriptional regulatory elements between prokaryotic and 
eukaryotic systems [41]. Comparison of many regulatory 
elements in the promoters of eukaryotic, bacterial, and 
viral genes has revealed an important element, known as 
the TATA box in eukaryotes, which bears some resembl- 
ance to the Pribnow box in prokaryotic promoters [42,43]. 
The ospA upstream control region, like those from several 
other B. burgdorferi surface antigens, is very A/T-rich, 
and TATA-like motifs can be found [25, 341. Thus, these 
elements may be functional both in bacteria and eukary- 
otic cells. In addition, bacterial CAMP-responsive elem- 
ents have been shown to be functional in eukaryotic cells 
[44]. A more detailed analysis of the ospA promoter is 
required to identify the cis-acting element(s) operative in 
the regulation of transcription. 
Our findings have several important implications. It is 
tempting to speculate that bacteria have evolved strategies 
to express at least parts of their genome in mammalian 
cells to escape host defense mechanisms. In light of recent 
observations that foreign genes can be most effectively 
expressed in mammalian cells when associated with circu- 
lar double-stranded plasmid DNA [14, 15, 18, 191, it may 
be of importance to note that the OspA protein is encoded 
by a gene located on a linear plasmid with covalently 
closed ends [41]. Thus, it is possible that those genes of 
B. burgdorferi which are encoded by plasmids, including 
OspA and other outer surface lipoproteins, are expressed 
in the eukaryotic environment. 
For B. burgdorferi, one could envisage a situation in which 
antigens from spirochetes, including OspA, are introduced 
into the antigen-processing pathway by expression from 
respective linearkircular plasmid DNA taken up during 
phagocytosis by host cells. This could result in MHC class I 
expression of OspA-derived peptides. The destruction of 
these spirochete-infected target cells by specific cytolytic 
Tcells may serve to weaken the phagocytic clearance of 
the spirochetes and lead to the liberation of still intact, sur- 
viving B. burgdorferi organisms which could either infect 
other cells or migrate to immuno-privileged sites. This 
hypothetical scenario is supported, at least partially, by 
previous findings indicating that spirochetes survive intra- 
cellularly [45, 461 and that they persist even in the pres- 
ence of optimal protective antibody responses [47]. 
We can only speculate whether OspA protein is expressed 
by muscle cells or professional APC resident in or circulat- 
ing through the muscle. It is clear from previous studies 
that injection of plasmid DNA leads to the expression of 
the encoded protein intracellularly and in the circulation 
[15, 18, 191. Our data show that OspA is expressed in 
amounts sufficient to induce efficient humoral and cellular 
immune responses. Most probably, the OspA protein is 
expressed in its nonlipidated form, since the lipid moiety 
of bacterial proteins is unique to prokaryotic organisms 
[48]. Whether this is of relevance for the quality or magni- 
tude of the immune response generated must await further 
detailed experimentation. The fact that no protective 
immunity was observed following treatment with pBosOs- 
pA17/48, despite its apparent ability to be transcribed 
(Fig. 3), may be due to the fact that the OspA protein pro- 
duced from this construct lacks the N-terminal leader 
sequence. This sequence may be important for guiding 
OspA to a cellular compartment involved in evoking an 
immune response. 
4.3 Vaccination of mice with plasmid DNA containing 
the OspA gene leads to protection against infection 
with B .  burgdorj-en 
The specific B and Tcell responses generated in BALB/c 
and AKIUN mice after immunization with plasmids con- 
taining the ospA gene including its own upstream control 
region are similar to those observed after challenge with 
rlipOspA [5,6]. This is true with respect to the generation 
of OspA-specific antibodies, including their isotypes 
(Fig. 2 [32]). Moreover, plasmid DNA-vaccinated mice 
were readily protected against infection. In addition, 
adoptive transfer of IS from these mice led to full protec- 
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tion of recipient SCID mice upon challenge with spiroche- 
tes. The protective capacity of transferred immune sera 
was similar to that obtained following rlipOspA immuniza- 
tion as indicated by comparable amounts of LA-2 equival- 
ent antibodies which have recently been shown to corre- 
late positively with protection [38, 391. 
Plasmid DNA vaccination of AKFW and BALB/c mice 
also leads to activation of OspA-reactive T cells. The find- 
ing that supernatants of Tcells restimulated in vitro only 
contained IFN-y but no IL-4 suggests that this immuniza- 
tion protocol results in a preferential recruitment of Thl  
cells. Although in line with previous studies in the human 
system [49], the data are in contrast to those of recent 
reports in the mouse [50, 511. Following infection with 
B. burgdorferi, both IFN-y and IL-4 was detectable in 
lymphocyte cultures upon restimulation with borrelial 
sonicate in vitro: C3WHeJ Tcells produced high levels of 
IFN-y and low levels of IL-4, whereas the contrary was 
true for BALBlc Tcells. However, it should be noted that 
in spite of the polarized cytokine patterns observed in the 
two mouse strains, the production in vitro of IL-4 by the 
respective T cell populations is always orders of magnitu- 
des lower compared to IFN-y when incubated with either 
spirochetal or polyclonal stimuli [50-521. Thus, at present 
it is not known whether the lack of IL-4 production in our 
study is due to the distinct priming protocol or to a lower 
sensitivity of the cytokine assay system used. 
Our data do not reveal whether plasmid DNA vaccination 
leads to the activation of both CD4' and CD8' Tcells. 
However, preliminary experiments showed that immuniza- 
tion of mice with pOspA results in the generation of T cells 
reactive to MHC class-11-specific peptides [52]. This is of 
importance in light of the finding that the development of 
optimal protective antibody responses to OspA is depen- 
dent on T helper cells [6]. 
No side effects have been observed in mice vaccinated 
with either of the plasmid DNA applied in this study. 
Together with recent results showing that mice tolerant to 
OspA develop arthritis similar to nontransgenic litterma- 
tes [53], the present data argue against this lipoprotein 
being a critical factor in the development of arthritis, as 
was recently suggested in the human system [54, 551. 
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